Emer O. Hanrahan - Concepedia

Author

Emer O. Hanrahan

The University of Texas MD Anderson Cancer Center

Also Known As

E. Hanrahan, E. O. Hanrahan, E.O. Hanrahan, Emer Hanrahan, Emer O Hanrahan, Emer O. Hanrahan

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center AstraZeneca (United Kingdom)AstraZeneca (Singapore)Hospital Clínico Universitario de Valencia Thoracic Surgery Foundation

About

Emer O. Hanrahan is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, pathology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	298
2	Pathology	5	5	298
3	Health Sciences	3	3	93
4	Immunology	1	1	10
5	Pharmacology	1	1	10

Emer O. Hanrahan

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller Ana M. González-Angulo, Jennifer K. Litton, Kristine Broglio, Journal of Clinical Oncology	2009	464
Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma Emer O. Hanrahan, Ana M. González-Angulo, Sharon H. Giordano, Journal of Clinical Oncology	2007	351
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial Rafael Rosell, Urania Dafni, Enriqueta Felip, The Lancet Respiratory Medicine MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentEgfr Mutations	2017	182
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer Emer O. Hanrahan, Heather Lin, Edward S. Kim, Journal of Clinical Oncology	2009	131
Rapid Needle-Out Patient-Rollover Time after Percutaneous CT-guided Transthoracic Biopsy of Lung Nodules: Effect on Pneumothorax Rate Ailbhe C. O’Neill, C. F. McCarthy, Carole A. Ridge, Radiology	2011	94
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer Emer O. Hanrahan, Anderson J. Ryan, Helen Mann, Clinical Cancer Research	2009	87
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer Tina Cascone, Li Xu, Heather Lin, Clinical Cancer Research	2017	84
Combined‐modality treatment for isolated recurrences of breast carcinoma Emer O. Hanrahan, Kristine Broglio, Aman U. Buzdar, Cancer Surgical OncologyCombined‐modality TreatmentCancer TherapeuticsHealth SciencesBreast Oncology	2005	73
A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck Emer O. Hanrahan, Merrill S. Kies, Bonnie S. Glisson, American Journal of Clinical Oncology	2009	42
Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma Emer O. Hanrahan, Kristine Broglio, Deborah Frye, Cancer	2006	29

Page 1